TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the current accepted standard of care. These results signal the start of a new chapter for people with drug-resistant (DR)-TB, who currently face lengthy treatment regimens. Read Here.
top of page
Recent Posts
See AllThis week, the WHO recommended four new treatments for patients with MDR-TB. Three of the regimens were from the End TB trial, and one...
130
The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to...
290
Johnson and Johnson successfully applied for a patent extension on bedaquiline; however, in a big win for LMI countries, the company has...
200
bottom of page
Comments